Table 3.
Cardiovascular adverse events in participants ≥60 years of age with a cardiovascular medical history
| CV AEs, n (%) | Quarterly fremanezumab | Monthly fremanezumab | Placebo | |
|---|---|---|---|---|
| (CM/EM: 675 mg/PBO/PBO) | (EM: 225/225/225 mg) | (CM: 675/225/225 mg) | ||
| Participants with CV medical history | (n = 30) | (n = 6) | (n = 14) | (n = 23) |
| ≥1 CV AE | 1 (3) | 0 | 2 (14) | 1 (4) |
| AEs with incidence ≥1 participant in any treatment/dose group | ||||
| Palpitations | 0 | 0 | 1 (7) | 1 (4) |
| Hypertensive crisis | 0 | 0 | 1 (7) | 0 |
| Supraventricular tachycardia | 1 (3) | 0 | 0 | 0 |
| Participants without CV medical history | (n = 44) | (n = 40) | (n = 32) | (n = 57) |
| ≥1 CV AE | 0 | 0 | 2 (6) | 0 |
| AEs with incidence ≥1 participant in any treatment/dose group | ||||
| Hot flush | 0 | 0 | 1 (3) | 0 |
| Hypertension | 0 | 0 | 1 (3) | 0 |
CM, chronic migraine; EM, episodic migraine; PBO, placebo; CV, cardiovascular; AE, adverse event